ClearPoint Neuro, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Tables)

Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2021

Stockholders’ Equity - Schedule of Share-Based Compensation for Director Fees

The following is information regarding the number of shares issued to directors as payment for director fees in lieu of cash for the three and six months ended June 30, 2021 and 2020:

Three Months Ended June 30,
2021			2020
1,820			9,832

Six Months Ended June 30,
2021			2020
3,829			19,563

Stockholders’ Equity - Schedule of Stock Option Activity

Stock option activity under all of the Company’s Plans during the six months ended June 30, 2021 is summarized below:

	Shares		Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾ (in thousands)
Outstanding at January 1, 2021		1,806,092	$	7.12	$	20,760
Granted		40,030		20.61
Exercised		447,900		2.59
Expired / terminated		18,500		20.46
Outstanding at June 30, 2021		1,379,722	$	8.19	$	14,916

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.

Stockholders’ Equity - Schedule of Common Stock Warrant Activity

Warrants have generally been issued in connection with financing transactions and for terms of up to five years. Common stock warrant activity for the six months ended June 30, 2021 was as follows:

	Shares			Weighted-average Exercise price per share		Intrinsic Value⁽¹⁾ (in thousands)
Outstanding at January 1, 2021		3,082,987		$	3.82	$	37,379
Exercised		(1,593,971	)		3.07
Outstanding at June 30, 2021		1,489,016		$	4.62	$	21,653

⁽¹⁾	Intrinsic value is calculated as the estimated fair value of the Company’s stock at the end of the related period less the option exercise price of in-the-money options.